Improved Orthopedic Implant Surface Coatings

骨内金属植入物是医学和牙科中常用的异体器械。的 整形外科和牙科市场持续增长，植入物的适应症正在扩大。人们认为需要通过控制愈合和重塑过程中的界面反应性来改善植入物的成功愈合（骨整合）和长期结果。骨生物学知识的增长和生物技术的扩展允许目前考虑通过使用天然或合成生物活性剂（生长因子、细胞外基质蛋白、小分子）来指定骨内金属植入物的一种或多种界面生物活性。相关界面作用的潜在实例包括由BMP指定的骨诱导、由OPG指定的再吸收的抑制、由BMP指定的骨诱导的抑制、由OPG指定的骨诱导。 炎症TNFR拮抗剂，或通过抗微生物或防污分子预防感染。每一种界面作用对于目前使用的一种或多种骨内金属植入物的应用都具有相关意义。将一种或多种生物活性直接指定到骨内金属植入物表面所面临的主要障碍是指定剂与金属表面的附着，而不损害植入物的潜在机械性能或指定生物活性剂的功能。 在这个建议中，我们提出了一种新的方法来指定钛种植体表面的生物活性。Affinergy开发了一种通用的方法来创建目标表面特异性生物聚合物，该生物聚合物将指定的生物活性剂不可逆地结合到骨内植入物表面。这些指定和接枝生物聚合物被称为“界面生物材料”（IFBM）。双功能IFBM具有以下独特优点：a）提供必需的表面结合特异性，B）包含用于广泛应用的稳健化学，以及c）提供指定广泛范围的相关或独立的生物活性的能力。 活动到一个单一的金属表面。本阶段I SBIR提案的目标是确认IFBM方法，以确定钛骨内植入物的生物活性。本研究结果将为IFBM修饰的骨内种植体直接转化为临床应用奠定基础。

Endosseous metallic implants are common alloplastic devices used in medicine and dentistry. The orthopedic and dental marketplace continues to grow and indications for implants are expanding. There is a perceived need to improve both the successful healing (osseointegration) and the long term outcome of implants by control of interfacial reactivity during healing and remodeling. The growth of knowledge of bone biology and the expansion of biotechnology permits the present consideration of specifying one or more interfacial biologic activities to an endosseous metallic implant by use of a natural or synthetic bioactive agent (growth factor, extracellular matrix protein, small molecule). Potential examples of relevant interfacial actions include osteoinduction specified by BMPs, inhibition of resorption specified by OPG, inhibition of inflammation TNFR antagonists, or prevention of infection by anti-microbial or anti-fouling molecules. Each interfacial action is of related significance to one or more endosseous metallic implant application used today. The main obstacle facing the direct specification of a biological activity or activities to an endosseous metallic implant surface is the attachment of the specifying agent to the metallic surface without compromising the underlying mechanical properties of the implant or the function of the specifying bioactive agent. In this proposal we present a novel approach for specifying the biologic activity of titanium implant surfaces. Affinergy has developed a generalized approach to creating target surface-specific biopolymers that irreversibly bind specifying bioactive agents to the endosseous implant surface. These specifying and grafting biopolymers are termed a "interfacial biomaterials" (IFBM). The bi-functional IFBM has the unique advantages of a) providing requisite surface binding specificity, b) comprising robust chemistry for broad-based applications and c) offering capacity to specify a wide range of associated or independent biological activities onto a single metallic surface. The goal of this phase I SBIR proposal is to validate the IFBM approach to specifying a biological activity to titanium endosseous implants. The results of this research will establish the foundation for direct translation of IFBM-modified endosseous implants to clinical applications.